kyron.bio
Emilia McLaughlin has a strong background in biochemistry and molecular biology, with experience in research, lecturing, event coordination, and entrepreneurship. Currently, Emilia is the founder of kyron.bio, a company focused on revolutionizing drug production. Emilia holds a PhD in Cell and Molecular Biology from the prestigious Pasteur Institute and has received multiple research grants for their work. Emilia's experience includes internships at companies like Amgen and the Zoological Society of London, where Emilia conducted research on malaria vaccines and amphibian pathogens, respectively. Emilia's diverse experiences and education highlight their expertise in the field of biotechnology.
This person is not in any teams
kyron.bio
Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical industry.